NCT03088488

Vitamin D and Periodontitis

Completed Last updated 23 March 2017

What this trial tests

trial testing fasting venous blood samples in Alveolar Bone Loss in 60 participants. Completed in 21 April 2016.

Timeline

1 June 2015

Primary endpoint
15 March 2016

21 April 2016

Quick facts

Lead sponsor	Ordu University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	60
Start date	1 June 2015
Primary completion	15 March 2016
Estimated completion	21 April 2016

Drugs / interventions tested

• fasting venous blood samples

Conditions studied

• Alveolar Bone Loss — all drugs for Alveolar Bone Loss →

Sponsor

Ordu University

Who can join

Adults 25 to 45, any sex, with Alveolar Bone Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vitamin D has become important for periodontal disease due to play a role in autoimmunity, bone mineral metabolism and inflammation. Our aim was to investigate the relation between serum 25-hydroxy vitamin D levels, clinical periodontal parameters and blood serum biomarkers. The subjects were evaluated in 2 groups as chronic periodontitis (n= 30) and periodontally healthy subjects (n= 30). Periodontal parameters and fasting venous blood samples were taken from the subjects to assess each patient's periodontal status and for biochemical analyses (25-hydroxy vitamin D (25-OH vit D), osteoprotegerin (OPG), receptor activator of nuclear kappa B ligand (RANKL), C-telopeptide (CTx), tumor necrosis factor-α (TNF-α)).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.